Utama › Leukemia Biphenotipik Akut
Kajian klinikal Leukemia Biphenotipik Akut sedang mengambil peserta di AS
37 kajian untuk Leukemia Biphenotipik Akut sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Seattle, WA15 kajian
- Houston, TX11 kajian
- New York City, NY10 kajian
- Atlanta, GA9 kajian
- Durham, NC8 kajian
- Memphis, TN7 kajian
- Chicago, IL7 kajian
- Charlotte, NC6 kajian
- Aurora, CO6 kajian
- Baldwin Park, CA6 kajian
- Los Angeles, CA6 kajian
- Portland, OR6 kajian
- Philadelphia, PA6 kajian
- Dallas, TX6 kajian
- San Diego, CA5 kajian
- Boston, MA5 kajian
- San Francisco, CA5 kajian
- Tampa, FL5 kajian
- Clifton, NJ5 kajian
- Greenburgh, NY5 kajian
- Columbus, OH5 kajian
- Nashville, TN5 kajian
- Fort Worth, TX5 kajian
- Cincinnati, OH5 kajian
- Minneapolis, MN5 kajian
- Mountain View, CA4 kajian
- Jacksonville, FL4 kajian
- Denver, CO4 kajian
- Milwaukee, WI4 kajian
- Greenville, NC4 kajian
- St. Louis, MO4 kajian
- Kansas City, MO4 kajian
- Akron, OH4 kajian
- Baltimore, MD4 kajian
- Cleveland, OH4 kajian
- Gainesville, FL4 kajian
- Orange, CA4 kajian
- Queens, NY4 kajian
- Edison, NJ4 kajian
- Washington, DC4 kajian
Mengikut negeri
- Alabama3 kajian
- Alaska3 kajian
- Arizona3 kajian
- Arkansas3 kajian
- California15 kajian
- Colorado8 kajian
- Connecticut3 kajian
- Delaware3 kajian
- Florida9 kajian
- Georgia9 kajian
- Hawaii3 kajian
- Idaho3 kajian
- Illinois7 kajian
- Indiana4 kajian
- Iowa4 kajian
- Kentucky4 kajian
- Louisiana4 kajian
- Maine3 kajian
- Maryland4 kajian
- Massachusetts5 kajian
- Michigan4 kajian
- Minnesota6 kajian
- Mississippi3 kajian
- Missouri5 kajian
- Nebraska4 kajian
- Nevada3 kajian
- New Hampshire3 kajian
- New Jersey6 kajian
- New York11 kajian
- North Carolina11 kajian
- North Dakota3 kajian
- Ohio8 kajian
- Oklahoma5 kajian
- Oregon6 kajian
- Pennsylvania6 kajian
- Rhode Island3 kajian
- South Carolina3 kajian
- South Dakota3 kajian
- Tennessee10 kajian
- Texas13 kajian
- Utah3 kajian
- Virginia3 kajian
- Washington15 kajian
- West Virginia3 kajian
- Wilayah Columbia4 kajian
- Wisconsin5 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Mengambil pesertaFasa 1
Umur 12 hingga 78 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Mengambil pesertaFasa 2
365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04375631Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07094750A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Mengambil pesertaFasa 1/2
30 Days · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04065399Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT03683433Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Mengambil pesertaFasa 1/2Sukarelawan sihat dialu-alukan
Sehingga umur 50 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT05322850Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Mengambil pesertaFasa 3
365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Mengambil pesertaFasa 2
Umur 1 hingga 18 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Mengambil pesertaFasa 1
Umur 1 hingga 30 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06177067Personalized NK Cell Therapy in CBT
Mengambil pesertaFasa 2
Umur 15 hingga 80 · Semua jantina · Dikemas kini 30 Jul 2026 · NCT02727803Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Mengambil pesertaFasa 2
6 Months – 65 Years · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Jul 2026 · NCT07046078Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Mengambil pesertaFasa 4
Umur 1 hingga 18 · Semua jantina · Dikemas kini 14 Jul 2026 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT07216443Allo HSCT Using RIC and PTCy for Hematological Diseases
Mengambil pesertaFasa 2
Sehingga umur 75 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT05805605Registry of Older Patients With Cancer
Mengambil pesertaKajian pemerhatian
Umur 65 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT01137825Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Mengambil pesertaFasa 1
Umur 18 hingga 70 · Semua jantina · Dikemas kini 23 Jun 2026 · NCT06551584211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Mengambil pesertaFasa 1/2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 22 Jun 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Mengambil pesertaFasa 1/2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 22 Jun 2026 · NCT03670966A Study of Revumenib and Mezigdomide in People With Leukemia
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jun 2026 · NCT04047641Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan
6 Months · Semua jantina · Dikemas kini 29 Mei 2026 · NCT04195633Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.